AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A ‐Mediated Lysosomal Dysfunction in APP / PS1 Mice
CNS Neuroscience & Therapeutics · 2026-04 · 32 (4)
DOI: 10.1002/cns.70910 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 28.04.2026. Verfasst von Da-Long He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Basic Medical Sciences, Hainan Medical University, Haikou, Chi…. Hauptthemen laut MEDLINE: Lysosomes, Group IV Phospholipases A2, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Both cytosolic phospholipase A2 (PLA2G4A)‐induced lysosomal membrane disruption and glycogen synthase kinase‐3 α / β (GSK3 α / β )‐mediated lysosomal dysfunction have been implicated in neurodegeneration, with a potential regulatory relationship between these two pathways. We recently identified AS1842856 (AS) as a suppressor of GSK3 α / β . This study was therefore designed to investigate whether AS mitigates Alzheimer's disease (AD) progression by targeting PLA2G4A to restore lysosomal homeostasis.
Methods
The therapeutic potential of AS was investigated in APP/PS1 mice by analyzing cognitive function, β ‐amyloid (A β ) load, and lysosomal integrity, with its mechanism of action further explored in N2a‐sw cells.
Results
AS treatment reduced GSK3 α / β expression in both APP/PS1 mice and N2a‐sw cells. This suppression led to decreased PLA2G4A levels, restoration of lysosomal membrane integrity, and enhanced lysosomal degradation of A β . Consequently, AS administration alleviated A β burden and improved cognitive function in APP/PS1 mice. Moreover, AS was found to inhibit NF‐κB‐mediated PLA2G4A expression. Knockdown experiments further revealed that reduced GSK3 β —but not GSK3 α —reproduced the suppressive effect on PLA2G4A.
Conclusion
Our study identified the GSK3 β /NF‐κB/PLA2G4A signaling axis as a novel therapeutic target in AD, and AS could inhibit this axis to mitigate A β pathology by promoting lysosomal degradation of A β .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Basic Medical Sciences, Hainan Medical University, Haikou, China.
- Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, Shenyang, China.
- First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
ORCID-Profile: Yong-Gang Fan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, D. L., Wu, Z., Jia, R. J., Wu, T. Y., Qiu, Y. M., & Fan, Y. G. (2026). AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A ‐Mediated Lysosomal Dysfunction in APP / PS1 Mice. CNS Neuroscience & Therapeutics, 32(4). https://doi.org/10.1002/cns.70910
Vancouver
He DL, Wu Z, Jia RJ, Wu TY, Qiu YM, Fan YG. AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A ‐Mediated Lysosomal Dysfunction in APP / PS1 Mice. CNS Neuroscience & Therapeutics. 2026;32(4). doi:10.1002/cns.70910
BibTeX
@article{He2026,
author = {He, Da-Long and Wu, Zheng and Jia, Rong-Jun and Wu, Ting-Yao and Qiu, Yi-Min and Fan, Yong-Gang},
title = {AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A ‐Mediated Lysosomal Dysfunction in APP / PS1 Mice},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {4},
doi = {10.1002/cns.70910}
}
EUVIMED